Abstract
Diabetes is a chronic metabolic disease characterized by hyperglycemia, which leads to oxidative stress due to an imbalance between by oxidant and antioxidant. Platelet-Rich Plasma (PRP) has been used in clinical settings to stimulate tissue repair and cell proliferation in various medical fields. Erythropoietin (EPO) has demonstrated protective effects on various tissues and has mitigatied ischemia-reperfusion injury and promoting tissue regeneration. The aim of this study was to evaluate the effects of PRP and EPO on the oxidant/antioxidant balance in diabetic rats. A total of 30 male rats were divided into five groups: 1. Control; 2. Diabetic control, diabetes was induced using streptozotocin (STZ); 3. Diabetic + PRP: PRP was administered subcutaneously at 0.5 mL/kg twice a week for four weeks in diabetic rats; 4. Diabetic + EPO: EPO was administered at 300 units/kg three times a week for four weeks in diabetic rats; and 5. Diabetic + PRP + EPO: A combination of PRP and EPO was administered for four weeks. Diabetic rats showed significant reductions in superoxide dismutase (SOD), glutathione peroxidase (GPX), and glutathione (GSH) levels,as well as an increase in malondialdehyde (MDA) concentration, compared to the control group (P <0.05). Compared to untreated diabetic rats, PRP and EPO treatments significantly increased SOD, GPX, and GSH quantities (P <0.05) and lowered MDA concentrations. The combination therapy group exhibited the greatest improvements in antioxidant activities. This study demonstrates that both PRP and EPO both exhibit significant antioxidant effects in diabetic rats, and that the combined treatment shows the most pronounced improvement in oxidative stress markers. These results lay the groundwork for the clinical applications of PRP and EPO in enhancing antioxidant defenses and reducing oxidative damage in diabetic patients.